Analyst Price Target is $14.00
▲ +426.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galectin Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 426.32% upside from the last price of $2.66.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Galectin Therapeutics. This Buy consensus rating has held steady for over two years.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.